Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
The drug will be given over a 14 weeks with six weeks titrating up, six weeks maintaining highest dose, and up to two weeks tapering down. Assessments will be collected following week 12 to measure change in olfactory function from baseline between the two study groups.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women between the ages 18 to 70 years
Residing within the states of Missouri or Illinois
Complaints of odors of certain things or everything are distorted
Olfactory dysfunction that has persisted for \>2 months after suspected COVID-19 infection
Ability to read, write, and understand English
You may not be if
History of olfactory dysfunction prior to COVID-19 infection
Any use of concomitant therapies specifically for the treatment of olfactory dysfunction
History of olfactory dysfunction of longer than 12 months
History of bipolar disorder as SSRIs can theoretically destabilize bipolar disorder
Participants with symptoms of depression as evidenced by a score of 10 or greater on the Patient Health Questionnaire-9 (PHQ-9).95 The PHQ-9 is a nine-item questionnaire designed to assess and aid in diagnosing patients with depression in clinical and community settings.
History of neurodegenerative disease (i.e., Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia)
History of chronic rhinosinusitis or sinus surgery
Pregnant or breastfeeding mothers.
Already enrolled in another COVID 19 medication trial or receipt of monoclonal antibody infusion.
Taking donepezil or fluoxetine (rationale: these drugs are S1R agonists) or sertraline (a S1R antagonist).
Participants taking theophylline, tizanidine, clozapine, or olanzapine (drugs with a narrow therapeutic index that are primarily metabolized by CYP 1A2, which is inhibited by fluvoxamine.
Taking another SSRI, unless at a low dose (e.g., escitalopram 5mg) such that adding fluvoxamine would not put patient at risk for serotonin syndrome.
Taking coumadin based on theoretical risk of increased bleeding with fluvoxamine.
Unable to provide informed consent.
Unable to perform the study procedures.
Clareo Health | Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia
